Compile Data Set for Download or QSAR
Report error Found 295 Enz. Inhib. hit(s) with all data for entry = 2467
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367598BDBM367598(US10227299, Example 288)
Affinity DataIC50: 3nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367317BDBM367317(Methyl (6RS)-4-oxo-3-(phenylamino)-2-(pyridin-4-yl...)
Affinity DataIC50: 3nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367372BDBM367372((6RS)-6-[(Ethylsulfanyl)methyl]-3-(phenylamino)-2-...)
Affinity DataIC50: 4nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367593BDBM367593(US10227299, Example 283)
Affinity DataIC50: 4nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367368BDBM367368(US10227299, Example 60 | N,N-Dimethyl-4-oxo-3-(phe...)
Affinity DataIC50: 4nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367367BDBM367367(US10227299, Example 61 | N-Methyl-4-oxo-3-(phenyla...)
Affinity DataIC50: 4nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367472BDBM367472(Methyl (6RS)-2-[3-(2-methoxyethoxy)pyridin-4-yl]-4...)
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367371BDBM367371((6RS)-3-(Phenylamino)-6-[(propan-2-ylsulfanyl)meth...)
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367507BDBM367507((6RS)-2-2-[(4-Fluorobenzoyl)amino]pyridin-4-yl-N,N...)
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367349BDBM367349((6RS)-6-Ethenyl-3-(phenylamino)-2-(pyridin-4-yl)-1...)
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367592BDBM367592(US10227299, Example 282)
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367412BDBM367412((6RS)—N-Methyl-N-(2-methylpropyl)-4-oxo-3-(ph...)
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367590BDBM367590(US10227299, Example 280)
Affinity DataIC50: 5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367454BDBM367454(Methyl (6RS)-2-2-[(4-fluorobenzoyl)amino]pyridin-4...)
Affinity DataIC50: 6nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367391BDBM367391((6RS)-6-[(Ethylsulfonyl)methyl]-3-(phenylamino)-2-...)
Affinity DataIC50: 6nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367357BDBM367357(N-[(6RS)-4-Oxo-3-(phenylamino)-2-(pyridin-4-yl)-4,...)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367455BDBM367455(Methyl (6RS)-4-oxo-3-(phenylamino)-2-2-[(1,3-thiaz...)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367469BDBM367469(Methyl (6RS)-3-anilino-2-[3-(cyclopropylmethoxy)py...)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367463BDBM367463(N-4-[(6RS)-6-(Azidomethyl)-4-oxo-3-(phenylamino)-4...)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367509BDBM367509((6RS)—N,N-Dimethyl-4-oxo-3-(phenylamino)-2-2-...)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367386BDBM367386((6RS)-2-(3-Fluoropyridin-4-yl)-N,N-dimethyl-4-oxo-...)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367597BDBM367597(US10227299, Example 287)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367334BDBM367334((6RS)—N,N-Dimethyl-4-oxo-3-(phenylamino)-2-(p...)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367384BDBM367384(N-(2-Hydroxyethyl)-N-methyl-4-oxo-3-(phenylamino)-...)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367432BDBM367432((6RS)—N,N-Diethyl-4-oxo-3-(phenylamino)-2-(py...)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367515BDBM367515(US10227299, Example 203 | (6RS)-3-Anilino-N,N-dlis...)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367595BDBM367595(US10227299, Example 285)
Affinity DataIC50: 7nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367339BDBM367339((6RS)-6-(Hydroxymethyl)-6-methyl-3-(phenylamino)-2...)
Affinity DataIC50: 8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367388BDBM367388((6RS)-2-(3-Fluoropyridin-4-yl)-N-(2-hydroxyethyl)-...)
Affinity DataIC50: 8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367502BDBM367502(N-(4-(6RS)-Oxo-3-(phenylamino)-6-[(propan-2-ylsulf...)
Affinity DataIC50: 8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367551BDBM367551(US10227299, Example 239 | N-4-[(6RS)-6-[(Ethylsulf...)
Affinity DataIC50: 8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367501BDBM367501(N-4-[(6RS)-6-[(Ethylsulfanyl)methyl]-4-oxo-3-(phen...)
Affinity DataIC50: 8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367508BDBM367508((6RS)-2-2-[(4-Fluorobenzoyl)amino]pyridin-4-yl-N-(...)
Affinity DataIC50: 8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367541BDBM367541(US10227299, Example 229 | N-4-[(6RS)-6-[(2-Methoxy...)
Affinity DataIC50: 8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367327BDBM367327((6RS)—N-Ethyl-N-methyl-4-oxo-3-(phenylamino)-...)
Affinity DataIC50: 8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367360BDBM367360((4E/Z)-5-[(6RS)-Oxo-3-(phenylamino)-2-(pyridin-4-y...)
Affinity DataIC50: 8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367474BDBM367474((6RS)-2-[3-(2-Methoxyethoxy)pyridin-4-yl]-N,N-dime...)
Affinity DataIC50: 8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367543BDBM367543(US10227299, Example 231 | N-(4-(6RS)-Oxo-3-(phenyl...)
Affinity DataIC50: 8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367346BDBM367346((6RS)-6-(Aminomethyl)-3-(phenylamino)-2-(pyridin-4...)
Affinity DataIC50: 8nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367326BDBM367326((6RS)—N-(2-Hydroxyethyl)-N-methyl-4-oxo-3-(ph...)
Affinity DataIC50: 9nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367359BDBM367359(Methyl (6RS)-2-[2-(acetylamino)pyridin-4-yl]-4-oxo...)
Affinity DataIC50: 9nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367342BDBM367342((6RS)-6-(Azidomethyl)-3-(phenylamino)-2-(pyridin-4...)
Affinity DataIC50: 9nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367574BDBM367574(US10227299, Example 262 | N-{4-[(6RS)-3-Anilino-6-...)
Affinity DataIC50: 9nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367468BDBM367468(N-4-[(6RS)-6-(Aminomethyl)-4-oxo-3-(phenylamino)-4...)
Affinity DataIC50: 9nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367594BDBM367594(US10227299, Example 284)
Affinity DataIC50: 9nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367600BDBM367600(US10227299, Example 291)
Affinity DataIC50: 10nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367599BDBM367599(US10227299, Example 290)
Affinity DataIC50: 10nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367462BDBM367462(Methyl (6RS)-2-[3-(2,2-difluoroethoxy)pyridin-4-yl...)
Affinity DataIC50: 10nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367596BDBM367596(US10227299, Example 286)
Affinity DataIC50: 10nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandChemical structure of BindingDB Monomer ID 367333BDBM367333((6RS)—N-Methyl-4-oxo-3-(phenylamino)-N-propyl...)
Affinity DataIC50: 10nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2019
Entry Details
US Patent

Displayed 1 to 50 (of 295 total ) | Next | Last >>
Jump to: